These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 9069450)

  • 1. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
    Schweitzer M; Tessier D; Vlahos WD; Leiter L; Collet JP; McQueen MJ; Harvey L; Alaupovic P
    Atherosclerosis; 2002 May; 162(1):201-10. PubMed ID: 11947915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
    Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
    Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The compositional abnormalities of lipoproteins in diabetic renal failure.
    Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P
    Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis.
    Attman PO; Alaupovic P
    Nephron; 1991; 57(4):401-10. PubMed ID: 2046821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
    Krause BR; Newton RS
    J Lipid Res; 1985 Aug; 26(8):940-9. PubMed ID: 3862732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
    Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
    Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein metabolism and renal failure.
    Attman PO; Samuelsson O; Alaupovic P
    Am J Kidney Dis; 1993 Jun; 21(6):573-92. PubMed ID: 8503411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
    Yang CY; Gu ZW; Xie YH; Valentinova NV; Yang M; Yeshurun D; Quion JA; Gotto AM
    Atherosclerosis; 1996 Sep; 126(1):105-16. PubMed ID: 8879439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency.
    Samuelsson O; Attman PO; Knight-Gibson C; Larsson R; Mulec H; Weiss L; Alaupovic P
    J Am Soc Nephrol; 1998 Aug; 9(8):1482-8. PubMed ID: 9697671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
    Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P
    Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
    Nestel P; Simons L; Barter P; Clifton P; Colquhoun D; Hamilton-Craig I; Sikaris K; Sullivan D
    Atherosclerosis; 1997 Mar; 129(2):231-9. PubMed ID: 9105566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.